Amgen’s melanoma drug shows promise in key trial

(Reuters) – Amgen Inc said its experimental and novel treatment for advanced melanoma met the main goal of a late-stage clinical trial by demonstrating a durable response in significantly more patients than a comparison treatment. The drug known as talimogene laherparepvec induced a durable response rate (DRR) – defined as a complete or partial tumor shrinkage lasting for at least six months – in 16 percent of patients, according to preliminary results. …

1 27 28 29 30 31 83